Trump Secures Regeneron Deal for Favored-Nation Pricing to Benefit Americans
President Donald J. Trump recently announced a significant agreement with Regeneron, marking the 17th collaboration focused on lowering prescription drug prices for Americans. This deal introduces a most-favored-nation (MFN) pricing structure, aligning U.S. drug costs with those of other developed countries.
Key Features of the Regeneron MFN Agreement
- The agreement provides MFN drug prices for all new Regeneron products.
- Medicaid programs in every state will gain access to these reduced prices.
- Americans will benefit from substantial savings, with costs potentially reaching hundreds of millions of dollars.
Impact on Patients and Innovative Treatments
Patients can expect to see drastic price reductions. For example, the cholesterol medication Praluent, typically priced at $537, will now be available for just $225 when purchased directly through TrumpRx. Additionally, Regeneron’s new gene therapy for genetic deafness, called Otarmeni, will be free for U.S. patients.
Investment in American Pharmaceutical Manufacturing
Alongside the price reductions, Regeneron announced plans to invest $27 billion in U.S. research, development, and manufacturing by 2029. This initiative aims to double the company’s manufacturing capacity in the United States, further securing the pharmaceutical supply chain.
Historical Context and Previous Agreements
President Trump has been proactive in engaging with pharmaceutical manufacturers to lower drug prices. The MFN pricing policy is part of a broader effort to ensure American patients receive fair pricing on medications. Since the initiation of this policy, 17 leading pharmaceutical companies now provide MFN pricing for their drugs, covering approximately 86% of the branded drug market.
The journey began on May 12, 2025, with an Executive Order mandating actions to align U.S. drug prices with those of comparable nations. Since then, various agreements have been established with other manufacturers, marking a pivotal shift in U.S. pharmaceutical pricing strategies.
Conclusion
This recent agreement with Regeneron underscores the administration’s commitment to making prescription drugs more affordable. Through expanded access to MFN pricing, American patients are positioned to benefit significantly from lower healthcare costs.
